Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John E Levine, MD
Icahn School of Medicine at Mount Sinai
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Duarte, California, United States
- Emory University
Atlanta, Georgia, United States
- Northwestern
Chicago, Illinois, United States
- the University of Kansas Cancer Center
Westwood, Kansas, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Mayo Clinical
Rochester, Minnesota, United States
- Columbia University
New York, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Mount Sinai Health System
New York, New York, United States
- Ohio State University
Columbus, Ohio, United States
- University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, United States
- Vanderbilt University
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2016
- Primary completion
- 10 Dec 2020
- Completion
- 21 Nov 2021
- Last update posted
- 21 Oct 2022
- Registered enrollment
- 76
- Registry id
- NCT02133924
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.